Trial
NCT03890289
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Fondazione Italiana Linfomi - ETS
Collaborators
—
Condition
Follicular Lymphoma
Intervention
Idelalisib
Why stopped
Study was halted prematurely due to safety, since tocity stopping rules have been met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-21